SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (9425)3/29/1999 10:14:00 PM
From: Robert K.  Read Replies (5) | Respond to of 17367
 
I warned you all about your narrow focus on meningo. This is just the tip of the iceberg IMO. Contemplate this for starters.....>
>http://www.psoriasis.org/volunteer/xoma.html



To: Bluegreen who wrote (9425)3/29/1999 10:22:00 PM
From: LarryS  Respond to of 17367
 
FDA more or less a formality...don't think so.
I don't think any deals, amendments, or changes have
taken place. I think Neuprex will go the LONG route
of all successfully tested drugs. A plan was approved
based on number of deaths...now we just have to wait.

MAYBE, if we are a couple deaths away from the goal after the season is over the DSMB can then say "enough".



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News